Morning Breakouts

Latest California Healthline Stories

Lack of FDA Approval for Genetic Test Kit Halts Sales

The pharmacy chain Walgreen said Wednesday that it will hold off on selling genetic testing kits made by San Diego-based Pathway Genomics after FDA said the kits could not be sold without regulatory approval. The kits were expected to be sold for $20 and for additional fees would identify a person’s risks for certain diseases, mutations or adverse drug reactions. Pathway Genomics said it is communicating with FDA about the kit. San Diego Union-Tribune et al.

Senator Seeking Answers on Mammogram Program Cuts

Sen. Jenny Oropeza has sent a letter asking California Health and Human Services Secretary Kim Belshé to provide information about the number of mammograms provided after the state scaled back its Every Woman Counts breast cancer screening program for low-income women. CHHS has said it aims to reduce mammogram recipients to 259,000 this fiscal year, down from 311,000 last year. AP/San Francisco Chronicle.

Report: 6.5M Californians Under 65 Have Pre-Existing Conditions

In a new, California-specific report, Families USA finds that about one in five nonelderly Californians have a pre-existing condition that could prohibit them from obtaining health coverage in the individual market. Such individuals could benefit from a provision in the health reform law that bans insurers from denying coverage based on pre-existing conditions. Los Angeles Times‘ “Booster Shots” et al.

San Diego Company To Sell Genetic Tests in Drug Stores

San Diego-based Pathway Genomics has announced plans to sell its genetic testing kits in roughly 6,000 Walgreens stores nationwide beginning this week. The tests analyze individuals’ DNA variations to predict their risk for diabetes, heart disease, certain types of cancer and other medical conditions. Some experts have expressed concern about the accuracy of the testing kits and the need for physician interpretation of results. Washington Post et al.

Study: Screening Rates Linked to Financial Incentives

Rates of cervical cancer and diabetic retinopathy screenings were higher when physicians received financial incentives to conduct such tests and were lower when the rewards stopped, according to a study by British researchers, who looked at Kaiser Permanente physicians. Kaiser Permanente offered incentive payments for administering diabetic retinopathy tests from 1999 to 2003 and for cervical cancer screenings between 1999 and 2000 and from 2005 to present. Los Angeles Times‘ “Booster Shots.”

Jones Calls for Review of All Recent Health Plan Rates

Assembly member and Insurance Commissioner candidate Dave Jones (D-Sacramento) is calling upon the Department of Insurance to examine recent rate filings by health insurance companies, in light of an independent auditor finding flaws with the methodology Anthem Blue Cross used to calculate premium increases. Insurance Department spokesperson Darryl Ng said the department “has a rigorous system in place to review rate filings.” The department, however, cannot reject rate increases. Sacramento Bee.